Clinical Trials In BMT: Ensuring That Rare Diseases and Rarer Therapies are Well Done

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1 SUPPL., 2012, Pages

  Shurin, Susan ^a   Krischer, Jeff ^b   Groft, Stephen C ^c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); FEASIBILITY STUDY; FOLLOW UP; FUNDING; HEALTH CARE COST; HEALTH CARE SYSTEM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; POLICY; PRODUCT DEVELOPMENT; QUALITY CONTROL; RARE DISEASE; SAMPLING; STATISTICAL PARAMETERS; STUDY DESIGN; TOXICITY;

BONE MARROW TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; HUMANS; RARE DISEASES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855393641     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.10.030     Document Type: Article

References (12)

1. Small Clinical Trials: Issues and Challenges 2001, The National Academies Press, Washington, DC. C.H. Evans, S.T. Ilstad (Eds.).
2. Lagakos S. Clinical trials and rare diseases. N Engl J Med 2003, 348:2455-2456.
3. Wilcken B. Rare diseases and the assessment of intervention: what sorts of clinical trials can we use?. J Inherit 2001, 24:294-298.
4. Venance S., Herr B.E., Griggs R.C. Challenges in the design and conduct of therapeutic trials in channel disorders. Neurotherapeutics 2007, 4:199-204.
5. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), February 2010.
6. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program 2010, The National Academies Press, Washington, DC, Available at:. http://www.nap.edu/catalog/12879.html, S.N. Nass, H.L. Moses, J. Mendelsohn (Eds.).
7. Groft S.C., de la Paz M.P. Rare diseases-avoiding misperceptions and establishing realities: the need for reliable epidemiological data. Adv Exp Med Biol 2010, 686:3-14.
8. Forrest C.B., Bartek R.J., Rubinstein Y., Groft S.C. The case for a global rare-diseases registry. Lancet 2011, 377:1057-1059.
9. Rubinstein YR, Groft SC, Bartek R. Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB).
10. Contemp Clin Trials. 2010;31:394-404.
11. Griggs R.C., Batshaw M., Dunkle M., et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab 2009, 96:20-26.
12. Field MJ, Boat TF, editors. Rare Diseases and Orphan Products: Accelerating Research and Development. IOM (Institute of Medicine). Washington, DC: The National Academies Press, 2010.